Last reviewed · How we verify
NCT06226363
Phase I Study of LNF1901 in Advanced Malignant Tumors
Phase 1 trial testing LNF1901 Monoclonal Antibody Injection in Advanced Malignant Tumors in 82 participants. Not yet recruiting.
1 February 2025
Quick facts
| Lead sponsor | Shandong New Time Pharmaceutical Co., LTD |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 82 |
| Start date | 1 February 2024 |
| Primary completion | 1 February 2025 |
| Estimated completion | 1 February 2027 |
Drugs / interventions tested
- LNF1901 Monoclonal Antibody Injection — full drug profile →
Conditions studied
- Advanced Malignant Tumors — all drugs for Advanced Malignant Tumors →
Sponsor
Shandong New Time Pharmaceutical Co., LTD — full company profile →
Who can join
18 and older, any sex, with Advanced Malignant Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter, open, phase I dose-escalation and dose-expansion study to evaluate the safety, tolerability, initial antitumor efficacy, PK and immunogenic characteristics of LNF1901 in patients with advanced malignancies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06226363
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Malignant Tumors
Currently open trials in the same condition.
- NCT07038005 — A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors · Phase 1 · recruiting
- NCT07016490 — A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors · Phase 1 · recruiting
- NCT06877650 — First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors · Phase 1, PHASE2 · recruiting
- NCT06764771 — A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors · Phase 1 · active not recruiting
- NCT06223841 — A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors · Phase 1, PHASE2 · recruiting
Other Shandong New Time Pharmaceutical Co., LTD trials
Trials by the same sponsor.
- NCT07046273 — Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes · Phase 3 · not yet recruiting
- NCT07312188 — A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT06206915 — Phase I Study of XZ120 in Malignant Tumors · Phase 1 · not yet recruiting
- NCT07396506 — Bioequivalence Study of Dronedarone Hydrochloride Tablets in Healthy Subjects Under Fasting Conditions · NA · completed
- NCT07478133 — Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in Humans · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06226363 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shandong New Time Pharmaceutical Co., LTD
- Last refreshed: 26 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06226363.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing